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ABSTRACT 
 
Human steroidogenic cytochrome P450 17A1 (CYP17A1) is a bifunctional enzyme that 
performs both hydroxylation and lyase reactions, with the latter required to generate androgens 
that fuel prostate cancer proliferation.  The steroid abiraterone, the active form of the only FDA-
approved CYP17A1 inhibitor, binds the catalytic heme iron, nonselectively impeding both 
reactions and ultimately causing undesirable corticosteroid imbalance.  Some non-steroidal 
inhibitors reportedly inhibit the lyase reaction more than the preceding hydroxylase reaction, 
which would be clinically advantageous, but the mechanism is not understood.  Thus, the non-
steroidal inhibitors seviteronel and orteronel and the steroidal inhibitors abiraterone and 
galeterone were compared with respect to their binding modes and hydroxylase vs. lyase 
inhibition.  Binding studies and X-ray structures of CYP17A1 with non-steroidal inhibitors 
reveal coordination to the heme iron like the steroidal inhibitors.  (S)-Seviteronel binds similarly 
to both observed CYP17A1 conformations.  However, (S)-orteronel and (R)-orteronel bind to 
distinct CYP17A1 conformations that differ in a region implicated in ligand entry/exit and the 
presence of a peripheral ligand.  To reconcile these binding modes with enzyme function, side-
by-side enzymatic analysis was undertaken and revealed that neither the non-steroidal 
seviteronel or (S)-orteronel inhibitors demonstrated significant lyase selectivity, but the less 
potent (R)-orteronel was 8- to 11-fold selective for lyase inhibition.  While active site iron 
coordination is consistent with competitive inhibition, conformational selection for binding of 
some inhibitors and the differential presence of a peripheral ligand molecule suggest the 
possibility of CYP17A1 functional modulation by features outside the active site. 
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INTRODUCTION 
Among American men, prostate cancer is the most frequently diagnosed cancer and 
second-leading cause of cancer-related deaths (Edwards et al., 2014).  More than 80% of prostate 
cancers rely on androgens for tumor growth (Geller, 1993; Yin and Hu, 2014) and blocking their 
production can hinder disease progression.  Traditional androgen deprivation therapy targets the 
gonadotropin-releasing hormone receptor to ultimately inhibit testicular androgen production.  
However, adrenal androgens are still produced, often requiring coadministration of androgen 
receptor antagonists (Yin and Hu, 2014).  Despite these measures, most patients relapse within 
24 months with castration-resistant prostate cancer (Gomez et al., 2015) fueled by androgens 
from the adrenal gland or tumor (Montgomery et al., 2008).  Castration-resistant prostate cancer 
can be treated by inhibition of cytochrome P450 17A1 (CYP17A1), a required steroidogenic 
enzyme in all such tissues. 
CYP17A1 converts 21-carbon steroids to 19-carbon androgens in two chemical 
transformations (Arlt et al., 2002).  First, 21-carbon pregnenolone or progesterone is 
hydroxylated (Figure 1A).  The 17a-hydroxypregnenolone product can undergo a second, 17,20-
lyase reaction in the same active site to yield 19-carbon dehydroepiandrosterone, the androgen 
precursor for all sex steroids (Figure 1A).  17a-Hydroxylated steroids are also intermediates in 
glucocorticoid biosynthesis (Gilep et al., 2011) (Figure 1A).  Thus, mutations or clinical 
inhibition impacting both CYP17A1 reactions block androgen and glucocorticoid production.  
Glucocorticoid deficiency drives adrenocorticotropin hormone secretion, resulting in 
mineralocorticoid overproduction manifested clinically as hypertension, hypokalemia, and 
peripheral edema (Auchus, 2001).  This occurs in prostate cancer patients treated with the 
otherwise effective, first-in-class CYP17A1 inhibitor abiraterone acetate (Attard et al., 2008).  
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Abiraterone acetate is an ester prodrug rapidly hydrolyzed in vivo to the active alcohol form.  
Abiraterone (Table 1) is essentially the substrate pregnenolone with addition of a pyridine ring 
(Potter et al., 1995).  The pyridine coordinates the heme necessary for both CYP17A1-mediated 
reactions (Figure 1B) (DeVore and Scott, 2012).  Abiraterone effectively reduces serum 
androgens (O'Donnell et al., 2004; Ryan et al., 2010) and increases overall survival (Fizazi et al., 
2012) in prostate cancer patients, but the associated hypertension and peripheral edema reaction 
require prednisone coadministration (Attard et al., 2012). 
Several new CYP17A1 inhibitors have entered clinical trials (Table 1), including the 
steroidal inhibitor galeterone (VN/124-1 or TOK-001) (Handratta et al., 2005) and non-steroidal, 
naphthalene-based inhibitors (S)-orteronel (TAK-700) (Yamaoka et al., 2012) and (S)-seviteronel 
(VT-464) (Rafferty et al., 2014).  These non-steroidal inhibitors reportedly selectively inhibit the 
lyase reaction while sparing the 17-hydroxylase activity necessary for glucocorticoid 
biosynthesis.  The reported selectivity is modest (5- (Yamaoka et al., 2012) and 10-fold (Rafferty 
et al., 2014) for (S)-orteronel and (S)-seviteronel, respectively), but improved over that of 
abiraterone (0.1- to 1.4-fold (Potter et al., 1995; Yamaoka et al., 2012; Rafferty et al., 2014)).  
No selectivity information is available for galeterone.  Reports of lyase-selective inhibition are 
intriguing as all of these inhibitors contain nitrogen-containing heterocycles, which often 
coordinate the heme iron and should indiscriminately inhibit both CYP17A1 reactions. However, 
there are no structures of CYP17A1 with non-steroidal inhibitors to inform on their binding 
modes. 
Additionally, functional comparisons between these inhibitors are frequently frustrated 
by differences between experimental conditions and systems used to evaluate them.  Both 17,20-
lyase and hydroxylase inhibition studies use a wide range of substrate concentrations, which can 
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influence the apparent IC50 depending on inhibition mode.  Additionally, the 17α-hydroxylase 
reaction has two different physiological substrates, progesterone and pregnenolone, which 
demonstrate distinct CYP17A1 affinities and are hydroxylated at different rates (Petrunak et al., 
2014), yet inhibition studies are typically conducted with a single hydroxylase substrate, the 
identity of which varies between reports.  To add complexity, CYP17A1 requires NADPH-
cytochrome P450 reductase for both reactions, whereas cytochrome b5 substantially augments 
only the 17,20-lyase reaction (Katagiri et al., 1995; Auchus et al., 1998).  The systems in which 
these partner proteins are produced and incorporated with CYP17A1 vary among inhibition 
studies.  Differences in expression system (yeast vs. Escherichia coli), relative amounts of 
enzyme system components, and preparation of enzyme system (microsomal vs. purified 
proteins vs. whole cell) can all undermine comparisons of IC50 values between studies. 
 The present study employs spectral binding studies and X-ray structures with the non-
steroidal inhibitors to reveal Fe coordination similar to steroidal inhibitors, but with 
conformational selection and a peripheral ligand binding pocket in some cases.  To probe the 
relationships between these binding modes and enzyme inhibition, both steroidal and non-
steroidal inhibitors were then rigorously evaluated and compared for their ability to selectively 
inhibit the CYP17A1 17,20-lyase reaction vs. both 17a-hydroxylase reactions. 
 
MATERIALS AND METHODS 
Materials 
Abiraterone and orteronel were purchased from Selleckchem (Houston, TX).  
Abiraterone is used in these studies instead of the prodrug abiraterone acetate (Zytiga®) because 
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abiraterone is the active form in vivo.  Galeterone was purchased from Chemexpress (Shanghai, 
China).   
Racemic seviteronel was synthesized as reported (Rafferty et al., 2014).  The racemic mixture 
was separated into enantiomers using a preparative HPLC with an IA chiral column (Chiralpak 
particle size 5 µm, dimensions 20mm x 250mm), a guard column (particle size 5 µm, dimensions 
21mm x 50mm), and an n-hexanes/isopropanol mobile phase (flow rate: 15 mL/min).  The 
retention times for (S)-seviteronel and (R)-seviteronel were 26.8 min and 28.2 min, respectively 
(measured on an IA chiral analytical column).  (S)-Seviteronel was isolated as 56 mg of a white 
powder with a specific rotation of [α]DRT –63 (c 0.5, methanol) and enantiomeric ratio (er) of 
99:1 as measured by analytical HPLC (Agilent 1100 series) with an analytical chiral column 
(Chiralcel OD-H, particle size 5 µm, dimensions 4.6 mm x 150mm) while using a mobile phase 
of n-hexanes:isopropanol. Similarly, (R)-seviteronel was isolated as 49 mg of a white powder: 
[α] DRT 59 (c 0.5, MeOH), and er = 99.6:0.4.  
The commercial orteronel was also separated into its enantiomers using the same 
preparative HPLC system described above, except employing an OD-H SFC column.  The 
retention times for (S)-orteronel and (R)-orteronel were 24.0 min and 25.7 min, respectively 
(measured on an OD-H/SFC chiral analytical column). All binding and enzymatic assays were 
accomplished with the individual enantiomers of each compound. 
All compounds were >95% pure as evaluated by HPLC by either the respective suppliers 
and/or in house evaluation. 
CYP17A1 with a modified 19-residue truncation of the N-terminus and addition of a C-
terminal 4 x histidine tag was expressed in Escherichia coli JM109 cells and purified as reported 
previously (Petrunak et al., 2014).  Human NADPH cytochrome P450 reductase bearing an N-
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terminal truncation and a mutation to decrease proteolysis (K59Q), and full-length rat 
cytochrome b5 were expressed and purified according to previously described protocols (Sandee 
and Miller, 2011). 
Spectral ligand binding assays 
Inhibitor binding to 100 nM CYP17A1 was monitored by measuring changes in 
absorbance associated with the heme cofactor as described previously (Petrunak et al., 2014). 
Notably, this low protein concentration was dictated by the very tight binding of most of the 
inhibitors (Copeland, 2013) and partially compensated for by using cuvettes with a 5 cm path 
length to improve signal/noise.  The change in absorbance after each addition of inhibitor (DA) 
was plotted vs. the inhibitor concentration (S).  Graphpad Prism was used to determine the Kd 
and DAmax with non-linear least-squares regression fitting to the Morrison equation, also known 
as the tight-binding equation, where E is total protein concentration and S is total ligand 
concentration: 
∆𝐴 = ∆𝐴$%& (𝐸 + 𝑆 + 𝐾,) − 𝐸 + 𝑆 + 𝐾, / − 4𝐸𝑆2𝐸  
Crystallization and Structure Determination 
CYP17A1 was co-crystallized with orteronel or (S)-seviteronel via hanging drop vapor 
diffusion.  Based on our experience with other CYP17A1 ligands with limited solubility, purified 
CYP17A1 was serially exchanged into ligand-containing buffer.  Ligand-free CYP17A1 in 50 
mM Tris HCl, pH 7.4, 20% glycerol, 500 mM NaCl, and 100 mM glycine was diluted 5-fold in 
the same buffer containing either 100 µM orteronel (a mixture of enantiomers from 
Selleckchem) or 500 µM (S)-seviteronel and concentrated together.  This dilution and 
concentration in ligand-containing buffer was repeated multiple times to saturate CYP17A1, 
followed by concentration to 29-30 mg/mL.  The solubility of (S)-seviteronel permitted addition 
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of additional ligand to a final concentration of 1 mM.  Emulgen-913 (Desert Biologicals) was 
then added to a concentration of 0.5% (v/v).  This protein/ligand/detergent stock solution (1 µl) 
was mixed with 1 µl precipitant to form 2 µL drops.  The precipitant solution used to crystallize 
CYP17A1 with orteronel was 175 mM Tris HCl, pH 8.0, 30% (w/v) PEG-3350, 200 mM Li2SO4, 
and 12% glycerol.  The precipitant solution used to crystallize CYP17A1 with (S)-seviteronel 
was 100 mM sodium cacodylate trihydrate, pH 6.5, 200 mM ammonium sulfate, and 30% (w/v) 
PEG-8000.  The 2 µL drop used to generate (S)-seviteronel crystals was seeded with 
microcrystals generated in a 1 µL drop via sitting drop vapor diffusion in a 1:1 ratio with 
precipitant.  The 2 µL drops were equilibrated against 750 µL of the respective precipitant at 20 
°C, whereas the 1 µL drops were equilibrated against 100 µL precipitant at the same 
temperature.  Crystals were cryoprotected using a 7:3 mixture of mother liquor to 80% glycerol 
and were flash cooled in liquid nitrogen. 
Data were collected on beamline 12-2 or 7-1 at the Stanford Synchrotron Radiation 
Lightsource and processed using XDS (Kabsch, 2010).  Parameters for data collection and 
refinement statistics are described in Table 2.  Structures were solved by molecular replacement 
in Phaser (McCoy et al., 2007) using a previous structure of CYP17A1 with heme cofactor (PDB 
ID: 3SWZ (DeVore and Scott, 2012)) as a search model and data to the corresponding resolution 
cutoff (2.2 Å for CYP17A1 with orteronel and 3.15 Å for CYP17A1 with (S)-seviteronel).  
Model-building and iterative refinement were performed using COOT (Emsley et al., 2010) and 
PHENIX (Adams et al., 2010), respectively.  Ligand models were generated using eLBOW in 
PHENIX (Adams et al., 2010).  Simulated-annealing 2Fo-Fc and Fo-Fc composite omit maps were 
calculated in PHENIX (Adams et al., 2010).  Figures were generated using PyMOL 
(Schrodinger, 2010). 
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Enzyme inhibition assays 
Inhibition of progesterone hydroxylation by both steroidal and non-steroidal compounds 
(0-30 µM) was evaluated using a 1:4 ratio of CYP17A1 (50 pmol) and human NADPH-
cytochrome P450 reductase (200 pmol) at a substrate concentration of 10 µM, which is the 
previously determined Km for this reaction (Petrunak et al., 2014).  This assay was carried out as 
previously described (DeVore and Scott, 2012; Petrunak et al., 2014), using HPLC/UV-vis to 
quantify 17α-hydroxyprogesterone.  Inhibition of pregnenolone hydroxylation by steroidal and 
non-steroidal compounds (0-60 µM) was evaluated using the same 1:4 ratio of CYP17A1 (50 
pmol) and human reductase (200 pmol) at a substrate concentration of 1 µM, which is the 
previously determined Km for this reaction (Petrunak et al., 2014).  17α-Hydroxypregnenolone 
17,20-lyase inhibition by steroidal and non-steroidal compounds (0-10 µM) was evaluated using 
the same 1:4 ratio of CYP17A1 (50 pmol) to human reductase (200 pmol), with the addition of 
rat cytochrome b5 (200 pmol) and using a substrate concentration of 1.2 µM, which is the 
previously determined Km for this reaction (Petrunak et al., 2014).  GC/MS was used to quantify 
the silylated products 17α-hydroxypregnenolone (for pregnenolone hydroxylase inhibition) and 
dehydroepiandrosterone (for 17α-hydroxypregnenolone 17,20-lyase inhibition) (Petrunak et al., 
2014).   All three assays were initiated by addition of NADPH, carried out for 20 min at 37 °C in 
a total volume of 500 µl (100 nM CYP17A1) as previously reported (Petrunak et al., 2014).  In 
no case was the amount of substrate converted to product greater than 6%.  Data were fit to the 
equation for log [inhibitor] vs. normalized response (Variable Slope) in Graphpad Prism.  IC50 
values are the average of two independent experiments spanning the entire inhibitor 
concentration range and are reported ± standard error.  Within each experiment, each individual 
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inhibitor concentration was evaluated in duplicate or triplicate and the variation in these 
technical replicates are typified by the error bars in Figure 8. 
 
RESULTS 
Binding of Non-steroidal Inhibitors to CYP17A1 
 To monitor non-steroidal inhibitor binding in the CYP17A1 active site, the purified 
enzyme was titrated with (S)-orteronel and (S)-seviteronel and changes in UV-vis spectra were 
monitored from 500 to 300 nm.  Since both compounds include a single stereogenic center, the 
corresponding (R)-orteronel and (R)-seviteronel enantiomers were also evaluated for binding 
affinity to CYP17A1.  Binding of all four non-steroidal compounds resulted in an increase in 
absorbance at 424 nm and a decrease in absorbance at 393-410 nm (Figure 2).  This observed 
spectral shift is consistent with a change in heme electronic configuration upon replacement of 
the iron-water complex with a complex in which the iron is coordinated to a ligand heteroatom 
(Jefcoate, 1978).  This observation suggests that the nitrogen heterocycles of the non-steroidal 
inhibitors participate in heme coordination similar to those of the steroidal inhibitors abiraterone 
(Figure 1B) and galeterone (DeVore and Scott, 2012). 
For each titration, the change in absorbance as a function of ligand concentration was fit 
to the Morrison equation, also known as the tight-binding equation, to determine the dissociation 
constant of the CYP17A1-inhibitor complex.  (S)-Orteronel, (R)-orteronel, and (S)-seviteronel 
demonstrated very high affinity, with estimated Kd values of 40 ± 7, 56 ± 8, and 31 ± 7 nM, 
respectively.  Such high affinity is clear from the titration data (Figure 3A), in which the change 
in absorbance is essentially linear with respect to ligand concentration until no free CYP17A1 
remains, beyond which no further absorbance change occurs.  The result is a poor fit even to the 
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Morrison equation.  Binding of CYP17A1 to steroidal inhibitors abiraterone and galeterone 
previously resulted in tight binding and similar deviations (DeVore and Scott, 2012).  Therefore, 
the estimated Kd values probably represent the upper limit for these Kd values and these ligands 
likely bind much more tightly than estimated.  In contrast, (R)-seviteronel bound to CYP17A1 
with lower affinity, demonstrating a more typical hyperbolic curve and a Kd of 290 ± 10 nM 
(Figure 3B).  Although a rank order affinity cannot be established for most of the non-steroidal 
inhibitors, (R)-seviteronel is clearly a lower affinity ligand for CYP17A1 compared to (S)-
seviteronel and both enantiomers of orteronel.  
Crystal Structure of CYP17A1 with Orteronel 
To probe the basis for the reported 5-fold selective inhibition of the 17,20-lyase vs. 
hydroxylase reactions, purified CYP17A1 was co-crystallized with commercial material 
purchased as (S)-orteronel (Selleckchem).  The resulting structure of CYP17A1 was determined 
at 2.2 Å resolution in the space group P212121.  This is the same space group as previous 
CYP17A1 structures with both steroidal inhibitors and steroid substrates (DeVore and Scott, 
2012; Petrunak et al., 2014). The overall protein structure was consistent with the 
aforementioned structures, with four molecules composing the asymmetric unit. Also in 
agreement with previous structures of CYP17A1, there is high structural similarity between 
molecules A and B (rmsd over all Cα = 0.28 Å), and between molecules C and D (rmsd over all 
Cα = 0.42 Å), but more substantial differences are observed when comparing molecules A/B 
against C/D (average rmsd over all Cα = 1.20 ± 0.02 Å).  These two CYP17A1 conformation 
primarily differ at the N-terminus and the region between the F and G helices, as described for 
previous structures of CYP17A1 (Petrunak et al., 2014).  
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on April 3, 2017 as DOI: 10.1124/dmd.117.075317
 at A
SPET Journals on A
ugust 13, 2019
dm
d.aspetjournals.org
D
ow
nloaded from
 
 
 
DMD # 75317 
 
13 
 Clear density was observed for orteronel in the active sites of all four CYP17A1 
molecules in the crystal, and unambiguously indicates that the ligand is coordinated to the heme 
iron (Figure 4), consistent with the spectral shifts observed upon ligand binding.  However, the 
remainder of the ligand density observed in the active sites of molecules A and B was 
significantly different compared to that observed in molecules C and D.  Ligand density in 
molecules C and D was clearly (S)-orteronel (Figure 4A), however, this ligand was clearly not a 
match for the density observed in the active sites of molecules A and B.  The inconsistent ligand 
density observed in the two different conformations of CYP17A1 led to in-house 
characterization of the commercially-purchased (S)-orteronel, which was found to actually 
contain both enantiomers of orteronel along with small amounts of an unidentified impurity. (R)-
Orteronel provides a good fit for the ligand density in molecules A and B (Figure 4B) and is 
consistent with the 2Fo-Fc map, although the Fo-Fc difference maps are not completely satisfied 
by modeling this ligand in a single orientation, which may indicate a small amount of disorder. 
(R)-Orteronel bound in the CYP17A1 active is oriented similar to steroidal substrates and 
inhibitors, at a 60° angle from the plane of the heme, with one face of the naphthalene ring 
positioned flat against the I helix and the oxygen of the amide substituent directed toward a 
residue on the F helix, asparagine 202 (Figure 5B).  This residue has been shown to hydrogen 
bond with the C3 substituent of steroidal inhibitors and substrates, and appears to participate in a 
hydrogen bond (distances of 3.4 and 3.0 Å for molecules A and B, respectively) with (R)-
orteronel as well. 
The orientation of (S)-orteronel in the active site of molecules C/D shares some 
characteristics with (R)-orteronel as well as steroidal inhibitors and substrates.  This ligand also 
forms an approximate 60° angle from the plane of the heme, with one face of the naphthalene 
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core positioned flat against the I helix.  However, in contrast to (R)-orteronel and steroidal 
inhibitors, (S)-orteronel is oriented toward the G helix (Figure 5A) instead of the F helix.  The 
amide substituent hydrogen bonds with arginine 239 (R239; H-bonding distance of 2.7 and 3.0 Å 
for molecules C and D, respectively) and aspartic acid 298 (D298; H-bonding distance of 2.7 and 
2.8 Å for molecules C and D respectively) on the I helix.  Even though the F and G helices and 
other features of the active sites are essentially the same, these differential interactions are 
correlated with the two distinct conformations of the intervening F/G region.   
Crystal Structure of CYP17A1 with (S)-seviteronel 
 Of the two non-steroidal CYP17A1 inhibitors to enter clinical trials, (S)-Seviteronel was 
reportedly the most selective, with 10-fold more potent 17,20-lyase inhibition (Rafferty et al., 
2014).  The crystal structure of CYP17A1 bound to (S)-seviteronel was determined at 3.1 Å in 
the space group P212121.  The asymmetric unit comprised four copies of CYP17A1, which were 
similar to previous structures of CYP17A1 with substrates and inhibitors, including that of 
CYP17A1 with orteronel.  As described above for the CYP17A1/orteronel structure, molecules 
A and B demonstrated very similar overall conformation, as did molecules C and D.  Less 
structural similarity was observed between molecules A/B and C/D because of the same 
conformational differences at the N-terminus and F/G loop observed in the previous CYP17A1 
structures. 
 Density corresponding to (S)-seviteronel is present in all four copies of CYP17A1 (Figure 
6A), and was consistent between all copies.  The density clearly indicates that the ligand is 
coordinated to the heme iron, consistent with the spectral shift observed upon ligand binding.  As 
with orteronel, the naphthalene ring is positioned flat against the I helix.  However, unlike the 
structures with all other CYP17A1 inhibitors, (S)-seviteronel does not appear to form hydrogen 
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bonds with any residues in the F or G helices (Figure 6B).  Instead, the hydroxyl group 
participates in a hydrogen bond with the backbone carbonyl of V482 (average distance over four 
molecules = 2.9 ± 0.1 Å), while one of the nitrogens of the triazole coordinated to the heme iron 
is positioned within hydrogen bonding distance of the T306 side chain (average distance over 
four molecules = 3.1 ± 0.2 Å). The difluoromethoxy substituents of the inhibitor can be modeled 
in varied orientations within the CYP17A1 active site depending on the molecule, but generally 
position the fluorine atoms within 3.0 Å of active site residues including asparagine 202 and 
arginine 239.  It is possible that the difluoromethoxy substituents participate in weak dipolar or 
multipolar interactions with the side chains of these residues.  
Peripheral ligand binding site 
 In all CYP17A1 complexes, both those determined here with nonsteroidal inhibitors and 
those reported previously with steroids, two distinct, well-defined conformations are observed 
for the residues between the F and G helices, though the positions of the flanking helices are 
largely conserved (Figure 7).  The membrane-embedded region between these helices has been 
implicated in access of hydrophobic ligands to the otherwise buried active site.  In the orteronel 
structure reported herein, strong, continuous density consistent with binding of a peripheral 
ligand was observed between the F/G loop and N-terminal residues (Fo-Fc map at 3s in Figure 
7), but in only one of the two CYP17A1 conformations (teal in Figure 7).  This is the same 
CYP17A1 conformation (molecules C/D) that binds (S)-orteronel.  The CYP17A1 conformation 
to which (R)-orteronel binds in the active site (molecules A/B) has a conformation of the F/G 
loop that does not permit peripheral ligand binding (magenta in Figure 7).  In the structure of 
CYP17A1 with (S)-seviteronel, electron density is observed in the peripheral binding site only 
for the CYP17A1 C/D conformation that also binds (S)-orteronel, but this electron density is 
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weaker in the (S)-seviteronel structure.  This may be due to lower ligand affinity, more disorder, 
or, more likely, the lower resolution of the (S)-seviteronel structure.  Most of the residues 
surrounding this peripheral ligand are hydrophobic, suggesting a site that might have relatively 
low specificity.  In the higher resolution structure with orteronel, this peripheral density was 
experimentally modeled as either orteronel enantiomer, as a combination of enantiomers, and at 
partial occupancies.  Based on decreases in R and Rfree and comparison of the electron density 
and the ligand contours, (R)-orteronel was the best match, but not good enough to 
unambiguously model (R)-orteronel.  A partially occupied, low-affinity peripheral steroid 
binding site has been identified in the F/G region of structures of the steroidogenic CYP21A2 
(Zhao et al., 2012; Pallan et al., 2015b). 
Inhibition of Targeted 17,20-Lyase Reaction 
 To probe and compare relationships between the Fe-N binding mode observed in crystals 
and in solution with the functional consequences, steroidal inhibitors (abiraterone and 
galeterone), non-steroidal inhibitors from clinical trials ((S)-orteronel and (S)-seviteronel), and 
their corresponding enantiomers ((R)-orteronel and (R)-seviteronel) were initially evaluated for 
inhibition of the 17,20-lyase reaction, which is desirable for treatment of prostate cancer.  IC50 
determination was conducted using the physiologically-relevant substrate 17α-
hydroxypregnenolone at a concentration corresponding to the previously determined Km of this 
reaction (1.2 µM (Petrunak et al., 2014)) and in the presence of cytochrome b5, which is the 
physiologically-relevant stimulator of the lyase reaction.  The resulting IC50 values are shown in 
Table 3. 
The FDA-approved, first-in-class CYP17A1 inhibitor abiraterone demonstrated the 
highest potency for 17,20-lyase inhibition.  The other steroidal inhibitor, galeterone, was ca. 3-
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fold less potent than abiraterone, but still showed higher potency than any of the non-steroidal 
inhibitors. Of the non-steroidal inhibitors, (S)-orteronel exhibited only 6-fold lower potency than 
abiraterone, while (R)-orteronel exhibited nearly 13-fold lower potency compared to abiraterone.  
Finally, (S)-seviteronel and (R)-seviteronel were 12-fold and ~140-fold less potent than 
abiraterone, respectively. 
Inhibition of Off-Target Progesterone and Pregnenolone Hydroxylation Reactions   
 Each inhibitor was subsequently also evaluated for inhibition of progesterone and 
pregnenolone hydroxylation reactions.  Such inhibition is undesirable for treating prostate 
cancer.  Consistent with the 17,20-lyase inhibition assay, these reactions were also performed 
using purified human CYP17A1 and NADPH cytochrome P450 reductase and substrate 
concentrations equal to the previously determined Km values of these reactions (10 µM and 1 µM 
for progesterone and pregnenolone hydroxylation, respectively) using the same experimental 
parameters.  Since the hydroxylase reactions do not appear to require cytochrome b5 
physiologically, this protein was not included in the in vitro enzyme system to prevent 
subsequent conversion of the hydroxylase product to the corresponding 19-carbon androgen via 
the 17,20-lyase reaction.  IC50 values are shown in Table 3. 
The rank order potencies for inhibition of the off-target hydroxylation reactions were 
similar to that of 17,20-lyase inhibition. Abiraterone displayed the greatest potency, followed by 
the other steroidal inhibitor, galeterone.  All four non-steroidal inhibitors demonstrated less 
potency than abiraterone and galeterone.  Of the non-steroidal inhibitors evaluated, (S)-orteronel 
was the most potent inhibitor of both pregnenolone and progesterone hydroxylase reactions, but 
was still 6- or 13-fold less potent than abiraterone, respectively.  The other non-steroidal 
inhibitor, (S)-seviteronel, was an equipotent inhibitor of the pregnenolone hydroxylation 
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compared to (S)-orteronel and the second most potent non-steroidal inhibitor of the progesterone 
hydroxylase reaction.  (R)-Orteronel demonstrated significantly lower affinity than its S 
enantiomer for inhibition of both hydroxylation reactions.  Consistent with poor inhibition of the 
17,20-lyase reaction and low binding affinity, (R)-seviteronel exhibited the lowest potency for 
inhibition of progesterone hydroxylation and thus was not evaluated further. 
Comparison of IC50 values for 17,20-lyase inhibition and progesterone or pregnenolone 
hydroxylation can be used to evaluate inhibitor selectivity for the targeted reaction (17,20-lyase) 
over the non-targeted reactions (progesterone and pregnenolone hydroxylase) (Table 3, 
representative data shown in Figure 8).  The most selective inhibitors exhibit high IC50 values for 
the off-target hydroxylase reaction and low IC50 values for the targeted 17,20-lyase reaction.   
Selectivity is defined herein as the ratio of 17-hydroxylase IC50/17,20-lyase IC50.  A selectivity 
factor of 1 therefore indicates no selectivity for 17,20-lyase reaction, while higher selectivity 
factors indicate more selectivity toward desired inhibition of the 17,20 lyase reaction.  All 
inhibitors evaluated were more effective in suppressing the 17,20-lyase reaction than either 17-
hydroxylase reaction, and therefore all have selectivity factors greater than 1.  The steroidal 
inhibitors abiraterone and galeterone demonstrated between 1.3 and 3.3-fold selectivity for 
17,20-lyase inhibition over hydroxylase inhibition.  The S enantiomer of non-steroidal orteronel 
showed little selectivity against pregnenolone hydroxylation (3.3-fold) and only slightly higher 
selectivity (4.5-fold) against progesterone hydroxylation (Figure 8A).  Its enantiomer, (R)-
orteronel, exhibited greater selectivity for inhibition of the targeted 17,20-lyase reaction over 
both progesterone hydroxylation (Figure 8B) and pregnenolone hydroxylation (8-fold and 11-
fold, respectively).  In contrast, the non-steroidal inhibitor (S)-seviteronel did not demonstrate 
significant selectivity for 17,20-lyase inhibition compared to the steroidal inhibitors (2.7- and 
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2.1- fold selectivity against progesterone and pregnenolone hydroxylation, respectively). 
Similarly, (R)-seviteronel demonstrated only 2.3-fold selectivity for 17,20-lyase inhibition 
against progesterone hydroxylase inhibition.  Due to its poor potency and lack of observed 
selectivity against progesterone hydroxylation, (R)-seviteronel was not evaluated for inhibition 
of pregnenolone hydroxylation. 
 
DISCUSSION 
Cytochrome P450 17A1 inhibitors that have undergone clinical trials have all been 
individually functionally evaluated in one context or another.  These in vitro studies typically 
determined IC50 values, which can vary depending on substrate concentration and other 
experimental conditions.  This is demonstrated by the wide range of reported values for 
abiraterone (Table 1), making it exceedingly difficult to compare between studies.  Such 
comparisons are becoming more essential with development of second-generation steroidal and 
non-steroidal inhibitors targeting selective inhibition of the 17,20-lyase reaction over 17α-
hydroxylation.  The current study uses tightly-defined conditions to determine IC50 values across 
inhibitors.  Such comparisons establish rank order potency and determine whether selective 
inhibition of the 17,20-lyase reaction is indeed possible for compounds that likely coordinate the 
heme. 
 Steroidal abiraterone and galeterone were the most potent for the desired inhibition of the 
17,20-lyase reaction.  This is consistent with binding data demonstrating very high affinity of 
these compounds for the CYP17A1 active site (DeVore and Scott, 2012).  Abiraterone exhibited 
the highest potency overall (IC50=36 ± 3 nM), broadly consistent with previous studies in 
microsomes and purified protein systems (3 and 27 nM (Potter et al., 1995; Yamaoka et al., 
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2012; Rafferty et al., 2014)).  Galeterone exhibited ~3-fold lower potency.  Since abiraterone and 
galeterone are both based on the steroidal scaffold, these differences suggest the galeterone’s 
benzimidazole coordinates the heme iron less effectively than abiraterone’s pyridine.  A previous 
report of galeterone as a more potent inhibitor than abiraterone in a whole cell system may 
reflect other factors including differences in cellular penetration (Handratta et al., 2005). 
The most potent non-steroidal inhibitor was (S)-orteronel (IC50 = 210 ± 20), which was 
5.8-fold less potent than abiraterone for inhibiting the 17,20-lyase reaction. (S)-Seviteronel 
exhibited lower potency (IC50 = 430 ± 40 nM; 12-fold lower than abiraterone).  The R 
enantiomers of both non-steroidal inhibitors demonstrated even lower potency for 17,20-lyase 
inhibition.  (R)-Orteronel was 2.2-fold less potent than (S)-orteronel, while (R)-seviteronel was 
~12-fold less potent than its S enantiomer. (R)-seviteronel also binds the CYP17A1 iron with a 
much lower affinity than (S)-seviteronel.  Overall, these results suggest S stereochemistry is 
advantageous for potent 17,20-lyase inhibition in these non-steroidal agents. 
Rank order potency determined by the current study is broadly consistent with the 
clinical success of CYP17A1 inhibitors pursued to date.  Abiraterone was highly successful in 
clinical trials, improving overall survival in Phase III clinical trials (Fizazi et al., 2012).  
Decreased potency for 17,20-lyase inhibition by (S)-orteronel when compared to abiraterone is 
consistent with its failure to achieve a similar end point (Saad et al., 2015).  Based on these 
results, it is improbable that an even less potent inhibitor of 17,20-lyase activity such as (S)-
seviteronel would demonstrate improved efficacy in a clinical setting--if overall survival is solely 
modulated by CYP17A1 inhibition.  However, this is almost certainly not the case, as steroidal 
inhibitors have been reported to both antagonize (Handratta et al., 2005; Richards et al., 2012) 
and cause degradation of the androgen receptor (Yu et al., 2014), and (S)-seviteronel has also 
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been reported to act as an anti-androgen (Toren et al., 2014).  Nonetheless, inhibition of 17,20-
lyase activity of CYP17A1 is a primary contributor to success of these compounds in a clinical 
setting. 
CYP17A1 inhibitors can also block 17α-hydroxylation necessary for glucocorticoid 
biosynthesis, resulting in side effects including hypertension and peripheral edema (Attard et al., 
2012; Fizazi et al., 2012).  Abiraterone selectivity for the 17,20-lyase reaction over the 17α-
hydroxylation reportedly ranges from 0.1-fold to 1.4-fold depending on the conditions used 
(Potter et al., 1995; Yamaoka et al., 2012; Rafferty et al., 2014). Using purified CYP17A1 and 
partner proteins, we observed 2- and 3.3-fold selectivity for 17,20-lyase inhibition over 
progesterone and pregnenolone 17α-hydroxylation, respectively.  Galeterone demonstrated ~1.5-
fold selectivity for 17,20-lyase inhibition over inhibition of either hydroxylation reaction, 
suggesting it may cause similar side effects. 
Non-steroidal inhibitors (S)-orteronel and (S)-seviteronel are reported to be 5- and 10-
fold more selective for 17,20-lyase inhibition compared to 17α-hydroxylase inhibition (Yamaoka 
et al., 2012; Rafferty et al., 2014).  Thus, they have been developed as CYP17A1 inhibitors with 
potentially improved side effect profiles.  In the current study, (S)-orteronel demonstrated 3.3- to 
4.5-fold selectivity for 17,20-lyase inhibition.  It is unknown if this slight increase in selectivity 
compared to abiraterone would significantly improve the side effects, as (S)-orteronel was still 
co-administered with prednisone in clinical trials (Saad et al., 2015). 
In the current study, (S)-seviteronel demonstrated only 2- and 3-fold lyase selectivity, 
contrasting with the 10-fold selectivity for lyase inhibition over pregnenolone 17α-hydroxylase 
inhibition previously reported in yeast microsome studies (Rafferty et al., 2014).  There are 
several possible explanations for this apparent discrepancy.  In earlier work the ratios of 
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CYP17A1 to cofactors NADPH-cytochrome P450 reductase and cytochrome b5 were either not 
known or not reported, and may have an effect on the enzymatic turnover, the Km, and IC50 
values.  Additionally, the hydroxylase substrate concentrations may have differed from the Km.  
Substrate concentrations >Km introduce bias against competitive inhibitors and could result in 
artificially high hydroxylase IC50 values.  Clinical trials for (S)-seviteronel are still recruiting, but 
similar selectivity to abiraterone suggests that this non-steroidal inhibitor may produce similar 
side effects. 
Both non-steroidal inhibitors in clinical trials include stereocenters with an S 
configuration.  These enantiomers were pursued in the clinical trials because they were more 
potent 17,20-lyase inhibitors than their R enantiomers (Kaku et al., 2011; Rafferty et al., 2014). 
There have been no previous reports on the selectivity of inhibition by the R enantiomers.  In the 
current study, (R)-seviteronel demonstrated significantly lower potency than (S)-seviteronel, with 
no significant difference in selectivity for the 17,20-lyase reaction compared to progesterone 
hydroxylation.  Although (R)-orteronel is much less potent for lyase inhibition, it exhibited better 
selectivity.  (R)-Orteronel inhibited the 17,20-lyase reaction 8-fold better than progesterone 
hydroxylation and 11-fold better than pregnenolone hydroxylation.  This indicates that the 
configuration of orteronel’s stereocenter can have an impact on selectivity for 17,20-lyase 
inhibition. 
Although (R)-orteronel’s decreased potency in suppressing 17,20-lyase activity would 
make it a poor candidate for clinical development, it could provide insights into possible 
mechanisms for selective 17,20-lyase inhibition.  The 2.2 Å crystal structure of CYP17A1 co-
crystallized with a racemic mixture of (S)- and (R)- orteronel revealed that (R)-orteronel binds 
exclusively to one of the two conformations typically observed for CYP17A1.  In this CYP17A1 
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conformation (molecule A/B), (R)-orteronel is coordinated to the heme iron and also hydrogen 
bonds with N202 of the F helix, like steroidal inhibitors (DeVore and Scott, 2012).  The second 
conformation of CYP17A1 (molecule C/D), differing especially in the region between helices F 
and G, appears to selectively bind (S)-orteronel (Figure 7).  (S)-Orteronel also coordinates the 
heme iron but does not interact with F-helix residues, instead hydrogen bonding with R239 on 
the G helix and D298 on the I helix.  Only this latter CYP17A1 conformation has an F/G loop 
that forms a peripheral ligand binding site.  This region of membrane P450 enzymes is highly 
flexible and embedded in the endoplasmic reticulum membrane.  Although both F/G 
conformations are observed in all CYP17A1 structures with various steroidal inhibitors and 
substrates determined to date, all of these ligands adopt the same orientation, regardless of 
CYP17A1 conformations.  However, a mix of (R)- and (S)-orteronel are not observed in the 
CYP17A1 active site.  Instead (S)-orteronel is selectively bound to the CYP17A1 F/G 
conformation accommodating a peripheral ligand, while (R)-orteronel selectively binds the 
active site of CYP17A1 displaying the alternate conformation of this loop that does not bind a 
peripheral ligand.   
Differing conformations of this F/G loop have generally been implicated in substrate 
access to P450 active sites (Poulos and Johnson, 2005).  In telost fish the processivity of the 
CYP17A1 reactions is correlated with whether or not orteronel is selective for 17,20-lyase 
inhibition over hydroxylase inhibition (Pallan et al., 2015a).  For substrates more likely to leave 
the active site after the initial hydroxylation and prior to the 17,20-lyase reaction, (S)-orteronel 
demonstrated ~10-fold selectivity for 17,20-lyase inhibition.  In contrast, for substrates less 
likely to dissociate from the active site between 17-hydroxylase and 17,20-lyase reactions, only 
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2-fold selectivity for 17,20-lyase inhibition was observed.  Similar processivity studies for 
human CYP17A1 with different substrates have not yet been reported. 
Steroid binding in the F/G region has now been reported for several human cytochrome 
P450 enzymes.  A structure of steroidogenic CYP21A2 revealed with a low-affinity, partially-
occupied steroid in this region(Pallan et al., 2015b).  CYP3A4, the major human drug 
metabolizing P450, binds progesterone in this region(Williams et al., 2004).  The F/G region is 
typically a major component of the most hydrophobic surface of mammalian P450 enzymes.  It 
is also thought to be buried in the membrane and the major entry point for generally hydrophobic 
substrates to access the active site.  Thus, steroid binding in this region may be adventitious 
association driven by hydrophobic interactions or part of an initial substrate docking region 
before steroids advance into the buried active site.  Although cooperativity is not apparent in (S)-
orteronel binding to CYP17A1, ligand binding to P450 enzymes is detected by observing 
spectral changes associated with interactions near the heme and peripheral ligand binding would 
not necessarily be apparent.  It is known that F/G residues play a role in the homotrophic 
cooperativity of progesterone metabolism in CYP3A4(Harlow and Halpert, 1998; Domanski et 
al., 2001), but the physiological significance of peripheral ligand binding should be further 
evaluated. 
In conclusion, rank order potency and selectivity were established for in vitro inhibition 
of CYP17A1, with steroidal compounds more potent than the non-steroidal inhibitors seviteronel 
and orteronel.  Ten-fold selectivity for 17,20-lyase inhibition previously reported for (S)-
seviteronel was not observed, but less potent (R)-orteronel was more selective (8- to 11-fold).  
Structures with non-steroidal inhibitors reveal coordination of the heme iron, but demonstrate 
that different conformations of the F/G region can correlate with the binding of distinct orteronel 
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enantiomers in the active site and the capacity for peripheral binding of a ligand molecule.  
While iron coordination of inhibitors in the active site is consistent with competitive, non-
selective inhibition, both conformational selection for binding of some inhibitors and the 
differential presence of a peripheral ligand raise the possibility of differentially modulating 
CYP17A1 function via features outside the active site.  Improved understanding of CYP17A1 
structure/function relationships could help inform the development of more selective inhibitors, 
thereby improving prostate cancer treatment.  
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PDB ID Codes:  The PDB ID codes for CYP17A1 bound to racemic orteronel and (S)-
seviteronel are 5IRQ and 5IRV, respectively.  Authors will release the atomic coordinates and 
experimental data upon article publication. 
  
This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on April 3, 2017 as DOI: 10.1124/dmd.117.075317
 at A
SPET Journals on A
ugust 13, 2019
dm
d.aspetjournals.org
D
ow
nloaded from
 
 
 
DMD # 75317 
 
36 
FIGURE LEGENDS 
 
Figure 1. A) CYP17A1 mediates two major types of reactions, initial 17α-hydroxylation (blue) 
of pregnenolone or progesterone, followed by a 17,20-lyase reaction (magenta) on 17α-
hydroxypregnenolone.  While only the latter 17,20-lyase reaction is necessary for androgen 
biosynthesis, downstream products of the hydroxylase reaction include important glucocorticoids 
such as cortisol.  Inhibition of CYP17A1 by abiraterone (green) inhibits both CYP17A1-
mediated reaction types, resulting in the desired net decrease in androgens but an undesirable 
decrease in glucocorticoids.  The decrease in glucocorticoids results in an overproduction of 
mineralocorticoids as a result of adrenocorticotropin hormone feedback.  B) Abiraterone (green 
sticks) inhibits both CYP17A1 reactions by directly coordinating the CYP17A1 heme (black 
sticks with red iron sphere at center) required for catalysis. 
Figure 2.  Difference spectra illustrate absorbance shifts associated with heteroatom 
coordination to the heme iron as (S)-orteronel is titrated into 100 nM CYP17A1 (shown).  
Similar shifts were observed for the other four non-steroidal inhibitors evaluated (not shown).  
Spectra with increasing inhibitor concentrations are shown from low to high concentrations (red 
to blue/violet).  The difference in absorbance between the resulting peak and trough 
(ΔAbsorbance) were used to evaluate the ligand binding affinity to CYP17A1. 
Figure 3. A) Binding of non-steroidal inhibitor (S)-seviteronel to 100 nM CYP17A1 deviates 
from the tight-binding equation, consistent with very high affinity for the enzyme.  The fit shown 
has an estimated Kd of 31 ± 7, which is likely the upper limit of the dissociation constant for this 
complex.  B) In contrast, titration of 100 nM CYP17A1 with (R)-seviteronel reveals much lower 
affinity (Kd= 290 ± 10 nM) and has a much better fit to the tight-binding equation. 
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Figure 4. The contrasting ligand density in molecules C/D (panel A) compared to molecules A/B 
(panel B) in the 2.2 Å structure of CYP17A1 with orteronel supports binding of different 
enantiomers of orteronel in different molecules of the structure ((S)-orteronel in panel A, (R)-
orteronel in panel B).  Simulated annealing 2Fo-Fc composite omit maps (contoured to 1.0 σ) are 
shown as blue mesh. (R)-orteronel, modeled into molecules A/B of the structure (panel B), does 
not fully satisfy electron density as indicated by the simulated annealing composite omit Fo-Fc 
map for molecule A (negative density shown in red mesh and positive density shown in green 
mesh, contoured to 3.0 σ), which may indicate a small amount of disorder.  The same Fo-Fc map 
for (S)-orteronel indicates an excellent match between the density and the ligand model and so is 
not shown for clarity. 
Figure 5. Interaction of A) (S)-orteronel and B) (R)-orteronel with CYP17A1 active site 
residues.  All distances shown are averages for molecules A and B (in panel A) or C and D (in 
panel B). 
Figure 6. The 3.1 Å structure of CYP17A1 with (S)-seviteronel.  A) (S)-seviteronel (orange 
sticks) binds in the CYP17A1 active site coordinated to the heme (black sticks) iron (red sphere).  
Electron density for ligand and heme (blue mesh) is a simulated annealing 2Fo-Fc composite 
omit map contoured to 1.00 σ.  B) Interactions between CYP17A1 active site and (S)-seviteronel.  
Distances shown are averages from all four molecules. 
Figure 7. (R)-orteronel (magenta) and (S)-orteronel (teal) bind selectively to two distinct 
conformations of CYP17A1.  A major structural difference between the two formations is the 
structure of the F/G loop, a region implicated in ligand entry and exit for other mammalian 
cytochrome P450 enzymes.  An unknown ligand (Fo-Fc map in green mesh at 3.0 σ) is present 
only in the conformation that binds (S)-orteronel (teal). 
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Figure 8. Differences in 17,20-lyase inhibition (solid lines) and progesterone hydroxylase 
inhibition (dashed lines) demonstrate less selectivity for 17,20-lyase inhibition by A) (S)-
orteronel compared to B) (R)-orteronel. 
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TABLES 
Table 1. Reported IC50 values for inhibitors of CYP17A1 that have undergone clinical trials 
Inhibitor FDA 
Approval 
Status 
Reported 17,20-
Lyase IC50 (nM) 
Reported 
17α-Hydroxylase IC50 
(nM) 
Reported 
17,20-Lyase 
Selectivitya 
 
Abiraterone 
Approved 2.9-800 (Potter et 
al., 1995; 
Handratta et al., 
2005; Yamaoka et 
al., 2012; Rafferty 
et al., 2014) 
1.5-72 (Potter et al., 
1995; Jagusch et al., 
2008; Yamaoka et al., 
2012; Al-Masoudi et 
al., 2014; Rafferty et 
al., 2014) 
0.1- to 1.4-fold 
(Potter et al., 
1995; Yamaoka 
et al., 2012; 
Rafferty et al., 
2014) 
 
Galeterone 
(TOK-001  
or VN/124-1) 
Phase III 
Clinical 
Trials 
47-300 (Handratta 
et al., 2005; 
Bruno et al., 
2011) 
N/Rb N/Rb 
 
(S)-Orteronel 
(TAK-700) 
Discontinued 
after Phase 
III Clinical 
Trials 
19-140 (Kaku et 
al., 2011; 
Yamaoka et al., 
2012) 
760 (Yamaoka et al., 
2012) 
5-fold 
(Yamaoka et 
al., 2012) 
HO
N
HO
N
N
O
N
H
N
NOH
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(S)-seviteronel 
(VT-464) 
Phase II 
Clinical 
Trials 
69 (Rafferty et al., 
2014) 
690 (Rafferty et al., 
2014) 
10-fold 
(Rafferty et al., 
2014) 
aVersus progesterone or pregnenolone hydroxylation 
bN/R: not reported 
  
O
O NH
N
N
F F
F F
HO
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Table 2. Crystallographic data collection and refinement statistics for CYP17A1 with 
nonsteroidal inhibitors orteronel and (S)-seviteronel. 
 CYP17A1/racemic orteronel CYP17A1/(S)-seviteronel 
Data Collection   
   Beamline SSRL 7-1 SSRL 12-2 
   Space Group P212121 P212121 
   Cell Dimensions (Å) 90.17, 153.20, 168.12 90.95, 153.50, 169.04 
   Molecules/a.u. 4 4 
   Resolution (Å)a 39.28-2.20 (2.32-2.20) 39.44-3.10 (3.27-3.10) 
   Total reflectionsa 871,993 (125,334) 142,288 (20,014) 
   Unique reflectionsa 118,993 (16,928) 43,069 (6,096) 
   Redundancya 7.4 (7.4) 3.3 (3.3) 
   Rpima 0.053 (0.608) 0.087 (0.579) 
   <I/σ(I)> a 14.0 (1.6) 8.4 (1.6) 
   Completeness (%)a 99.8 (99.0) 98.5 (96.5) 
Refinement   
   Resolution (Å) 39.29-2.20 39.44-3.10 
   No. reflections 117,964 42,930 
   R/Rfree (%) 20.13/24.86 19.51/24.80 
   Ramachandran (%)   
       Favored 96.07 94.67 
       Allowed 3.93 5.07 
       Outliers 0.00 0.27 
   No. atoms/B factors (Å2)   
       Protein 14,901/47.4 15,025/62.5 
       Ligand       92/44.5     112/44.5 
       Heme     172/33.7     172/48.7 
       Water     525/41.9         0 
   RMSD bond (Å) 0.005 0.004 
   RMSD angle (°) 0.618 0.810 
   Coordinate error  
   (max. likelihood based) (Å) 0.28 0.44 
aStatistics for highest resolution shell are shown in parentheses.  
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Table 3. Summary of IC50 values for 17α-hydroxypregnenolone 17,20-lyase inhibition (targeted 
reaction), progesterone and pregnenolone hydroxylation (off-target reactions), and resulting 
selectivity ratios.  IC50 values are the average of two independent experiments ± standard error.  
Within each experiment, each inhibitor concentration was evaluated in duplicate or triplicate. 
Inhibitor  
Lyase  
IC50 (nM) 
Progesterone 
Hydroxylase 
IC50 (nM) 
Progesterone 
Hydroxylase 
IC50 
Lyase IC50 
Pregnenolone 
Hydroxylase 
IC50 (nM) 
Pregnenolone 
Hydroxylase 
IC50 
Lyase IC50 
 
Abiraterone 36 ± 2 76 ± 5 2.1 ± 0.2 121 ± 7 3.3 ± 0.3 
Galeterone 100 ± 10 130 ± 10 1.3 ± 0.2 150 ± 20 1.5 ± 0.3 
(S)-orteronel 210 ± 20 950 ± 70 4.5 ± 0.5 700 ± 100 3.3 ± 0.6 
(R)-orteronel 460 ± 90 4000 ± 300 8 ± 2 5000 ± 1000 11 ± 3 
(S)-seviteronel 430 ± 40 1170 ± 90 2.7 ± 0.3 700 ± 100 2.1 ± 0.4 
(R)-seviteronel 5000 ± 1000 11300 ± 900 2.3 ± 0.5 N/Da N/Da 
 
aND: Not Determined 
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FIGURES 
 
Figure 1 
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Figure 2 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 8. 
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